The dawn of preventing respiratory syncytial virus lower respiratory tract infections in children
Respiratory syncytial virus (RSV) is the commonest cause of lower respiratory tract infection (LRTI) in children, particularly those aged <1 year. In South Africa (SA), increased hospitalisation rates during the RSV season, including access to intensive care facilities, place a huge burden o...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
South African Medical Association
2024-11-01
|
| Series: | South African Medical Journal |
| Subjects: | |
| Online Access: | https://samajournals.co.za/index.php/samj/article/view/2582 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860584898101248 |
|---|---|
| author | Z Dangor S A Madhi H Zar D Demopoulos |
| author_facet | Z Dangor S A Madhi H Zar D Demopoulos |
| author_sort | Z Dangor |
| collection | DOAJ |
| description |
Respiratory syncytial virus (RSV) is the commonest cause of lower respiratory tract infection (LRTI) in children, particularly those aged <1 year. In South Africa (SA), increased hospitalisation rates during the RSV season, including access to intensive care facilities, place a huge burden on the healthcare system. Furthermore, RSV-LRTI during early childhood may lead to long-term respiratory sequelae, including recurrent wheezing, asthma, and impairment of lung function. Recently, two new RSV prevention strategies have emerged: nirsevimab, a long-acting monoclonal antibody, and a maternal RSV vaccine. Both strategies have shown high efficacy in reducing RSV-LRTI hospitalisation in infants and are being considered for licensure in SA. Implementation of these prevention strategies, combined with public engagement and collaboration between stakeholders, could significantly reduce RSV-related morbidity and mortality in SA.
|
| format | Article |
| id | doaj-art-896eb43516314fa9a4a9532e504d3e7c |
| institution | Kabale University |
| issn | 0256-9574 2078-5135 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | South African Medical Association |
| record_format | Article |
| series | South African Medical Journal |
| spelling | doaj-art-896eb43516314fa9a4a9532e504d3e7c2025-02-10T12:25:27ZengSouth African Medical AssociationSouth African Medical Journal0256-95742078-51352024-11-011141210.7196/SAMJ.2024.v114i12.2582The dawn of preventing respiratory syncytial virus lower respiratory tract infections in childrenZ Dangor0S A Madhi1H Zar2D Demopoulos3South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South AfricaSouth African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South AfricaDepartment of Paediatrics and Child Health, Red Cross War Memorial Children’s Hospital, and South African Medical Research Council Unit on Child and Adolescent Health, Faculty of Health Sciences, University of Cape Town, South AfricaDepartment of Critical Care, Wits Donald Gordon Medical Centre and Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa Respiratory syncytial virus (RSV) is the commonest cause of lower respiratory tract infection (LRTI) in children, particularly those aged <1 year. In South Africa (SA), increased hospitalisation rates during the RSV season, including access to intensive care facilities, place a huge burden on the healthcare system. Furthermore, RSV-LRTI during early childhood may lead to long-term respiratory sequelae, including recurrent wheezing, asthma, and impairment of lung function. Recently, two new RSV prevention strategies have emerged: nirsevimab, a long-acting monoclonal antibody, and a maternal RSV vaccine. Both strategies have shown high efficacy in reducing RSV-LRTI hospitalisation in infants and are being considered for licensure in SA. Implementation of these prevention strategies, combined with public engagement and collaboration between stakeholders, could significantly reduce RSV-related morbidity and mortality in SA. https://samajournals.co.za/index.php/samj/article/view/2582RSV, LRTI, Children, Infant |
| spellingShingle | Z Dangor S A Madhi H Zar D Demopoulos The dawn of preventing respiratory syncytial virus lower respiratory tract infections in children South African Medical Journal RSV, LRTI, Children, Infant |
| title | The dawn of preventing respiratory syncytial virus lower respiratory tract infections in children |
| title_full | The dawn of preventing respiratory syncytial virus lower respiratory tract infections in children |
| title_fullStr | The dawn of preventing respiratory syncytial virus lower respiratory tract infections in children |
| title_full_unstemmed | The dawn of preventing respiratory syncytial virus lower respiratory tract infections in children |
| title_short | The dawn of preventing respiratory syncytial virus lower respiratory tract infections in children |
| title_sort | dawn of preventing respiratory syncytial virus lower respiratory tract infections in children |
| topic | RSV, LRTI, Children, Infant |
| url | https://samajournals.co.za/index.php/samj/article/view/2582 |
| work_keys_str_mv | AT zdangor thedawnofpreventingrespiratorysyncytialviruslowerrespiratorytractinfectionsinchildren AT samadhi thedawnofpreventingrespiratorysyncytialviruslowerrespiratorytractinfectionsinchildren AT hzar thedawnofpreventingrespiratorysyncytialviruslowerrespiratorytractinfectionsinchildren AT ddemopoulos thedawnofpreventingrespiratorysyncytialviruslowerrespiratorytractinfectionsinchildren AT zdangor dawnofpreventingrespiratorysyncytialviruslowerrespiratorytractinfectionsinchildren AT samadhi dawnofpreventingrespiratorysyncytialviruslowerrespiratorytractinfectionsinchildren AT hzar dawnofpreventingrespiratorysyncytialviruslowerrespiratorytractinfectionsinchildren AT ddemopoulos dawnofpreventingrespiratorysyncytialviruslowerrespiratorytractinfectionsinchildren |